EA201301173A1 - Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования - Google Patents

Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования

Info

Publication number
EA201301173A1
EA201301173A1 EA201301173A EA201301173A EA201301173A1 EA 201301173 A1 EA201301173 A1 EA 201301173A1 EA 201301173 A EA201301173 A EA 201301173A EA 201301173 A EA201301173 A EA 201301173A EA 201301173 A1 EA201301173 A1 EA 201301173A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
clonal strains
attenuated
viruses
vaccinating
Prior art date
Application number
EA201301173A
Other languages
English (en)
Inventor
Аладар А. Сзалэй
Нанхай Джордж Шен
Йонг А. Ю
Кьян Жанг
Original Assignee
Дженелюкс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженелюкс Корпорейшн filed Critical Дженелюкс Корпорейшн
Publication of EA201301173A1 publication Critical patent/EA201301173A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Заявлены клональные штаммы вирусов осповакцины. Также заявлены способы идентификации и выделения ослабленных и онколитических клональных штаммов из препаратов вируса. Также заявлены модифицированные рекомбинантные формы клональных штаммов. Клональные штаммы и препараты вируса могут быть использованы для способов диагностики и лечения, в частности для лечения и диагностики или мониторинга пролиферативных расстройств, в том числе опухолевых заболеваний, таких как солидные опухоли и рак крови, но не ограничиваясь ими.
EA201301173A 2011-04-15 2012-04-13 Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования EA201301173A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161517297P 2011-04-15 2011-04-15
US201161628684P 2011-11-04 2011-11-04
PCT/US2012/033684 WO2012142529A2 (en) 2011-04-15 2012-04-13 Clonal strains of attenuated vaccinia viruses and methods of use thereof

Publications (1)

Publication Number Publication Date
EA201301173A1 true EA201301173A1 (ru) 2015-08-31

Family

ID=46000400

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301173A EA201301173A1 (ru) 2011-04-15 2012-04-13 Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования

Country Status (8)

Country Link
US (2) US11149254B2 (ru)
EP (1) EP2697368B1 (ru)
JP (2) JP6415977B2 (ru)
CN (2) CN104093830A (ru)
CA (1) CA2836299A1 (ru)
EA (1) EA201301173A1 (ru)
ES (1) ES2733211T3 (ru)
WO (1) WO2012142529A2 (ru)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1281767A3 (en) * 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
DE602004018927D1 (de) 2003-06-18 2009-02-26 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
TWI531652B (zh) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
EP2171071B1 (en) 2007-06-15 2015-08-05 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
JP2010533718A (ja) * 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
EP2393921B1 (en) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
ES2759015T3 (es) 2010-02-10 2020-05-07 Mayo Found Medical Education & Res Métodos y materiales para tratar el cáncer
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
EP2825693B1 (en) 2012-03-15 2018-05-30 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2014047350A1 (en) * 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
JP6596411B2 (ja) 2013-03-14 2019-10-23 アイカーン スクール オブ メディシン アット マウント サイナイ ニューカッスル病ウイルス及びその使用
BR112015025697B1 (pt) 2013-04-10 2022-05-03 Tot Shanghai R&D Center Co., Ltd Cepa do vírus vaccinia mutante,uso da cepa do vírus vaccinia mutante e método para a produção de um produto de gene recombinante
CN103901207B (zh) * 2013-05-07 2016-02-10 上海良润生物医药科技有限公司 Cystatin S和CA15-3在制备诊断和预示乳腺癌标志物中的应用
CN103913574B (zh) * 2013-05-07 2016-04-06 上海良润生物医药科技有限公司 半胱氨酸蛋白酶抑制剂s与癌胚抗原的联合应用
HUE066593T2 (hu) 2013-08-22 2024-08-28 Univ Pittsburgh Commonwealth Sys Higher Education Immunoonkolitikus terápiák
KR102197374B1 (ko) * 2013-11-21 2020-12-31 코쿠리츠 다이가쿠 호우진 돗토리 다이가쿠 분열 촉진 인자 활성화 단백질 키나제 의존성 재조합 우두 바이러스(md-rvv) 및 이의 용도
KR20160137946A (ko) * 2013-11-22 2016-12-02 디엔에이트릭스, 인코포레이티드 면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스
CN103690569B (zh) * 2013-12-11 2016-11-02 天津亿海生物科技有限公司 重组腺相关病毒AAV-shCdc6制剂、其制备和应用
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
WO2015143221A1 (en) * 2014-03-19 2015-09-24 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3119427B1 (en) 2014-03-19 2018-12-26 Mayo Foundation for Medical Education and Research Methods and materials for treating cancer
EP2942390B1 (en) * 2014-05-07 2017-10-04 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Green microalgae lacking a functional DYRKP-1 gene, for use for increased production of feedstock
AU2015277059B2 (en) 2014-06-18 2021-06-17 Clear Gene, Inc. Methods, compositions, and devices for rapid analysis of biological markers
US10601532B2 (en) * 2015-01-18 2020-03-24 Lg Electronics Inc. Broadcast signal transmission apparatus, broadcast signal receiving apparatus, broadcast signal transmission method, and broadcast signal receiving method
WO2016123628A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Colorado, A Body Corporate Sequence specific and organism specific antimicrobials and related materials and methods
CN104611336B (zh) * 2015-02-09 2017-06-23 上海长海医院 融合基因ttty15‑usp9y及其作为前列腺癌标志物的应用
CN115300622A (zh) 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
WO2016149559A1 (en) * 2015-03-18 2016-09-22 Aladar Szalay Virotherapy with an antibody combination
GB201505860D0 (en) * 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
EP3283088A4 (en) 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
EP3298132A4 (en) * 2015-05-19 2019-02-13 British Columbia Cancer Agency Branch RECOMBINANT ONCOLYTIC VIRUSES AND THEIR APPLICATIONS
KR20160140075A (ko) 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
WO2016205429A1 (en) * 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
CN105039269A (zh) * 2015-07-24 2015-11-11 北京鼎成肽源生物技术有限公司 一种用于治疗非小细胞肺癌的新型病毒疫苗及其制备方法
JP2018526428A (ja) 2015-09-09 2018-09-13 ティーブイエーエックス バイオメディカル アイ，リミティド ライアビリティ カンパニー 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
AU2016369603A1 (en) 2015-12-18 2018-07-05 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
CA3015650A1 (en) 2016-02-25 2017-08-31 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
JP7034080B2 (ja) 2016-02-25 2022-03-11 メモリアル スローン ケタリング キャンサー センター ヒトｆｌｔ３ｌを発現する組換えｍｖａまたはｍｖａδｅ３ｌおよび固形腫瘍に対する免疫療法薬としてのそれらの使用
EP3454911A4 (en) * 2016-05-11 2019-11-13 Ohio State Innovation Foundation ONCOLYTIC VIRUSES COMPRISING A GENE ESRAGE AND METHODS OF TREATING CANCER
RU2621868C1 (ru) * 2016-06-24 2017-06-07 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор"" (ФБУН ГНЦ ВБ "Вектор") Рекомбинантный штамм VACΔ6 вируса осповакцины с нарушенными генами вирулентности C3L, N1L, J2R, A35R, A56R, B8R для получения живой культуральной аттенуированной вакцины против натуральной оспы и других ортопоксвирусных инфекций человека
CA3031416C (en) * 2016-07-21 2023-09-19 Kolon Life Science, Inc. Recombinant vaccinia virus and use thereof
CN110199018B (zh) 2016-08-09 2024-06-07 希望之城 嵌合痘病毒组合物及其用途
AU2017332367B2 (en) 2016-09-21 2021-12-23 Stephen H. Thorne High mobility group box i mutant
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CA3098246A1 (en) * 2017-05-05 2018-11-08 Instituto De Biologia Molecular E Celular - Ibmc Constitutively active profilin-1 for use in the therapy and/or treatment of a neurological disorder and/or for promoting neuronal regeneration, kit and products thereof
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US10851350B1 (en) 2017-06-27 2020-12-01 Genelux Corporation Bioreactor production of virus from adherent cells
JP7282697B2 (ja) * 2017-06-30 2023-05-29 ブイアイビー ブイゼットダブリュ 新規タンパク質細孔
CN107893057B (zh) * 2017-12-27 2021-02-19 北京华都诗华生物制品有限公司 鸡传染性支气管炎病毒弱毒株及其构建方法和应用
BR112020013715A2 (pt) * 2018-01-05 2020-12-01 Ottawa Hospital Research Institute vetores de vaccinia modificados
JP7074864B2 (ja) * 2018-01-19 2022-05-24 コーロン ライフ サイエンス インコーポレイテッド 組換えワクシニアウイルスおよびそれを含む医薬組成物
US11738093B2 (en) 2018-04-09 2023-08-29 Hope For Annabel AAV-mediated delivery of ATP1A3 genes to central nervous system
BR112020022181A2 (pt) * 2018-05-02 2021-02-09 Tonix Pharma Holdings Limited vírus vaccinia quimérico sintético
WO2020030672A1 (en) * 2018-08-10 2020-02-13 Pantherna Therapeutics Gmbh Recombinant nucleic acid construct
EP3847260A4 (en) * 2018-09-07 2022-09-07 SOTIO Biotech Inc. CHIMERIC RECEPTOR POLYPEPTIDES IN COMBINATION WITH TRANSMETABOLIC MOLECULES THAT MODULATE INTRACELLULAR LACTATE CONCENTRATIONS AND THERAPEUTIC USES THEREOF
CN109750056A (zh) * 2019-01-07 2019-05-14 西安医学院 去除天坛株vgf基因的打靶质粒及其制备方法
CN111487398B (zh) * 2019-01-25 2022-11-11 四川大学华西医院 血管瘤治疗的生物标记物
CA3131945A1 (en) * 2019-03-15 2020-09-24 Regeneron Pharmaceuticals, Inc. A loss of function rodent model of solute carrier 39 member 5
CN110082536B (zh) * 2019-04-17 2022-06-10 广州医科大学附属肿瘤医院 一种乳腺癌细胞标志物细胞因子群及其应用
US20220313761A1 (en) * 2019-05-14 2022-10-06 National University Corporation Tottori University Vaccinia virus that induces cell fusion and use thereof
CN110484628B (zh) * 2019-07-31 2022-06-14 扬州大学 一种金茅黑鸡腹脂性状相关的分子标记与应用
JP2022546539A (ja) * 2019-09-02 2022-11-04 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 粘液腫ウイルスを用いて癌を治療するための新しい腫瘍崩壊ウイルスプラットフォーム
CN110713962B (zh) * 2019-09-06 2022-06-21 南京农业大学 一株高产丙二酰辅酶a的基因工程菌及其构建方法和应用
CN110658167B (zh) * 2019-10-08 2021-12-14 天津师范大学 基于银-金属有机骨架材料作为荧光探针应用于叶酸检测的方法
CN111019877B (zh) * 2019-12-31 2022-04-19 浙江工业大学 一种产l-半胱氨酸的基因工程菌、构建方法及应用
CN111214496B (zh) * 2020-01-09 2022-03-22 浙江大学 一种重组溶瘤病毒在制备治疗淋巴瘤药物组合物中的用途
CN111440771A (zh) * 2020-03-17 2020-07-24 中山大学附属第三医院 一种含有clcn2纯合突变的白质脑病患者特异诱导多能干细胞系
CN111394389A (zh) * 2020-03-24 2020-07-10 中国农业科学院兰州兽医研究所 基于单质粒拯救系统的塞内卡病毒感染性克隆及构建方法和应用
CN111388674B (zh) * 2020-03-30 2022-05-03 四川省人民医院 Rps7和srp14基因在治疗肾功能不全或肾损伤中的应用
JP2023535124A (ja) * 2020-05-20 2023-08-16 フォグホーン セラピューティクス インコーポレイテッド がんを治療する方法
CN111808945B (zh) * 2020-06-30 2023-09-22 宁波市康宁医院(宁波市精神疾病预防控制中心、宁波市微循环与莨菪类药研究所) Gabrd基因在筛选抗海洛因复吸药物中的应用
CN111803508B (zh) * 2020-08-05 2024-01-19 江苏省中医院 雷公藤内酯醇在制备用于治疗car-t诱发的细胞因子释放综合征的药物上的用途
CN112083321B (zh) * 2020-09-17 2023-06-30 安庆师范大学 基于隐马尔可夫模型的电路测试方法、存储介质及装置
JP6915792B1 (ja) * 2020-10-01 2021-08-04 国立大学法人鳥取大学 広範囲遺伝子欠損を有する腫瘍溶解性ワクシニアウイルス
EP4222250A1 (en) 2020-10-02 2023-08-09 Genelux Corporation Bioreactor production of virus from adherent cells
CN112458033B (zh) * 2020-11-16 2023-01-24 四川农业大学 减毒鼠伤寒沙门菌及其构建方法与应用
CN114584999B (zh) * 2020-11-30 2023-08-15 中国移动通信集团山西有限公司 一种监测系统、方法、设备及计算机存储介质
KR20230135586A (ko) 2021-01-24 2023-09-25 마이클 데이비드 포레스트 Atp 합성효소 억제제 - 미용 및 치료 용도
US11883245B2 (en) * 2021-03-22 2024-01-30 Verb Surgical Inc. Deep-learning-based real-time remaining surgery duration (RSD) estimation
CN113203780B (zh) * 2021-05-13 2022-05-31 桂林电子科技大学 一种非诊断目的无标记适配体传感器检测gpc3的方法
CN113203781B (zh) * 2021-05-13 2022-05-31 桂林电子科技大学 一种非诊断目的基于RGO-CS-Hemin@Pt NPs纳米材料和适配体检测GPC3的方法
CN113238040B (zh) * 2021-05-18 2022-05-31 桂林电子科技大学 一种非诊断目的基于纳米复合材料的laps传感器检测gpc3方法
CN113308487B (zh) * 2021-05-28 2022-10-21 山东省淡水渔业研究院（山东省淡水渔业监测中心） 多种草鱼重组细胞因子及其制备方法和在协同增强草鱼免疫功能中的应用
CN113174339B (zh) * 2021-06-10 2022-08-02 广东省科学院微生物研究所(广东省微生物分析检测中心) 一株卵孢小奥德蘑高产菌株hmgim-t43及其选育方法
CN114369623B (zh) * 2022-01-12 2023-07-07 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用
CN114410683B (zh) * 2022-01-12 2023-11-28 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的RIM3-RNAi及其应用
CN114369562B (zh) * 2022-03-21 2022-05-31 中国农业科学院北京畜牧兽医研究所 一种提高5-氨基乙酰丙酸表达量的方法
CN114774468B (zh) * 2022-04-20 2022-12-20 温氏食品集团股份有限公司 一种等位基因分子标记及抗蓝耳病猪群体组建方法
CN114703115B (zh) * 2022-04-22 2023-09-29 集美大学 一种变形假单胞菌fliS基因沉默菌株和用途
CN114712392B (zh) * 2022-05-16 2022-11-25 西部医美生物科技成都有限公司双流医疗分公司 来自自体血液分离的免疫细胞制剂及其应用
CN115261485B (zh) * 2022-06-15 2024-05-31 安徽农业大学 一种地方鸡剩余采食量相关的分子标记及其应用
CN115575635A (zh) * 2022-09-28 2023-01-06 兰州大学第一医院 一种胆管癌诊断标志物及其筛选方法和应用
CN116287476A (zh) * 2023-04-28 2023-06-23 广东省第二人民医院（广东省卫生应急医院） Npr在辅助评估流感病毒感染严重程度中的新应用
CN116334010B (zh) * 2023-05-30 2023-08-29 中义(北京)健康研究院 一种重组单纯疱疹病毒及其制备方法和应用
CN117106102B (zh) * 2023-10-23 2024-02-06 中国医学科学院医学生物学研究所 肠道病毒多抗原表位融合蛋白、基因、疫苗及其制备方法
CN117327797B (zh) * 2023-12-01 2024-03-15 北京大学第三医院（北京大学第三临床医学院） 一种rrp1基因在治疗非小细胞肺癌中的应用
CN117373547B (zh) * 2023-12-08 2024-02-27 四川省医学科学院·四川省人民医院 一种可视化癌症基因关系显示方法和系统
CN118146351A (zh) * 2024-01-24 2024-06-07 华南农业大学 猪载脂蛋白apoe在筛选抗蓝耳病猪及防治猪蓝耳病中的应用
CN117737250B (zh) * 2024-02-21 2024-07-09 上海金翌生物科技有限公司 一种膀胱癌生物标志物甲基化水平检测的方法及试剂盒
CN118330237B (zh) * 2024-06-13 2024-08-23 四川大学华西医院 检测fli1蛋白表达水平的试剂在制备筛查肺结核的试剂盒中的用途

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS542336A (en) 1977-06-06 1979-01-09 Meiji Seika Kaisha Ltd Preventive and remedy for viral diseases
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
EP0037441B1 (en) 1980-03-10 1984-05-09 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and anti-tumor agent, process for production thereof and microorganism used therein
US4315914A (en) 1980-04-04 1982-02-16 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5155020A (en) 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
JPS60202827A (ja) * 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5221623A (en) 1986-07-22 1993-06-22 Boyce Thompson Institute For Plant Research, Inc. Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms
US5866136A (en) 1986-08-01 1999-02-02 Commonwealth Scientific And Industrial Organisation Recombinant vaccine
CA1308516C (en) 1987-07-06 1992-10-06 J. William Lown Oligopeptide anticancer and antiviral agents
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
ZA891067B (en) 1988-02-12 1990-04-25 Commw Scient Ind Res Org Pox virus vectors
DE69032841T2 (de) 1989-01-23 1999-05-12 Chiron Corp., Emeryville, Calif. Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
US5179078A (en) 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
CA2105277C (en) 1991-03-07 2006-12-12 William I. Cox Genetically engineered vaccine strain
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5718902A (en) 1991-06-17 1998-02-17 The Regents Of The University Of California Double recombinant vaccinia virus vaccines
GB9114468D0 (en) 1991-07-04 1991-08-21 Wellcome Found Antibody production
DE69229390T2 (de) 1991-08-26 1999-11-11 Immuno Ag, Wien Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
ATE218893T1 (de) 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
US6491905B1 (en) 1993-09-14 2002-12-10 The Uab Research Foundation Recombinant bacterial cells for delivery of PNP to tumor cells
US5707928A (en) 1993-09-28 1998-01-13 American Cyanamid Company Emulsifiable suspension concentrate compositions of imidazolinyl benzoic acids, esters and salts thereof, and dinitroaniline herbicides
US6416754B1 (en) 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
DE69535288T2 (de) 1994-05-13 2007-04-05 Thomas Jefferson University Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6217847B1 (en) 1994-07-01 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
DK0784483T3 (da) 1994-10-03 2001-03-26 Us Gov Health & Human Serv Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul
US5885971A (en) 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US6503703B1 (en) 1995-05-19 2003-01-07 Mount Sinai School Of Medicine Of New York University Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
DE69636120T2 (de) 1995-11-30 2006-11-30 The Board of Regents, The University of Texas System, Austin Verfahren und zusammensetzungen zur behandlung von krebs
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6391579B1 (en) 1996-02-01 2002-05-21 Albert Einstein College Of Medicine Of Yeshiva University Thyroid sodium/iodide symporter and nucleic acid encoding same
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
CN1264429A (zh) 1997-04-28 2000-08-23 抗癌股份有限公司 以绿荧光蛋白(gfp)为标记的肿瘤转移模型
US6251384B1 (en) 1997-04-28 2001-06-26 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6232523B1 (en) 1997-04-28 2001-05-15 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
HUP0003911A3 (en) 1997-10-09 2007-11-28 Pro Virus Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6573090B1 (en) 1998-12-09 2003-06-03 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
DK1175486T3 (da) 1999-05-04 2007-10-29 Anhydro Ltd Fremgangsmåde til konservering af virus og mycoplasma
AU5446700A (en) 1999-05-28 2000-12-18 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
CA2720361A1 (en) 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
US6589531B1 (en) 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
EP1257656A2 (en) 2000-01-26 2002-11-20 Chiron Corporation Recombinant aav packaging systems
EP1259629B1 (en) 2000-03-02 2005-07-20 Polymun Scientific Immunbiologische Forschung GmbH Recombinant influenza a viruses
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
US6872357B1 (en) 2000-11-22 2005-03-29 Quadrant Drug Delivery Limited Formulation of preservation mixtures containing sensitive biologicals to be stabilized for ambient temperature storage by drying
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
US7645456B2 (en) 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
US20040091995A1 (en) 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
EP1404375A1 (en) 2001-07-09 2004-04-07 Anticancer, Inc. Imaging infection using fluorescent protein as a marker
CA2449013C (en) 2001-07-23 2012-05-22 Onyx Pharmaceuticals, Inc. Viral mutants that selectively replicate in targeted human cancer cells
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
EP1281772A1 (en) 2001-07-31 2003-02-05 Aladar A. Szalay Light-emitting microorganisms and cells for tumour diagnosis/therapy
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
CN1596126A (zh) 2001-11-30 2005-03-16 埃西斯创新有限公司 疫苗
WO2003049117A2 (en) 2001-12-05 2003-06-12 Cangene Corporation Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
JP4550421B2 (ja) 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
US20030153065A1 (en) 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
WO2003078640A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
SI1407033T1 (sl) 2002-05-16 2006-06-30 Bavarian Nordic As Intergenske regije kot insercijska mesta v genomumodificiranega virusavakcinije Ankara (MVA)
EP1369491A1 (en) 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20030228261A1 (en) 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20060004191A1 (en) 2002-06-25 2006-01-05 Jhiang Sissy M Modified sodium iodide symporter proteins and genes for imaging and cancer therapy
EP2269618A1 (en) 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.
CA2500661A1 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
DE602004018927D1 (de) 2003-06-18 2009-02-26 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
EP1489164A1 (en) 2003-06-18 2004-12-22 Genelux GmbH Recombinant vaccinia viruses with modified F3 genes, uses thereof
EP1526185B1 (en) 2003-10-22 2012-09-12 Genelux Corporation Use of a microorganism or cell to induce autoimmunization of an organism against a tumor
ATE445017T1 (de) 2003-08-14 2009-10-15 Genelux Corp Methode zur herstellung eines polypeptides, einer rna oder einer anderen verbindung in tumorgewebe
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US20050214266A1 (en) 2004-03-12 2005-09-29 Oncolytics Biotech Inc. Combination of transplantation and oncolytic virus treatment
US20060193832A1 (en) 2005-02-04 2006-08-31 University Of Iowa Research Foundation Use of the sodium iodine symporter to effect uptake of iodine
CA2610265A1 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
KR20090004839A (ko) 2005-09-07 2009-01-12 제네렉스, 인코포레이티드 Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
EP1979000B1 (en) 2005-12-22 2011-07-13 Memorial Sloan-Kettering Cancer Center Method for detection of cancer cells using virus
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
JP5448840B2 (ja) 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
US20090081639A1 (en) 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
EP2171071B1 (en) 2007-06-15 2015-08-05 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
JP2010533718A (ja) 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
EP2212696B1 (en) 2007-10-25 2013-12-04 Genelux Corporation Systems and methods for viral therapy
EP2242516A1 (en) 2008-01-11 2010-10-27 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
US20120052003A9 (en) 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
ES2585242T3 (es) * 2008-09-19 2016-10-04 Etat Francais Représenté Par Le Directeur Central Du Service De Santé Des Armées Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
US20140086976A1 (en) 2012-08-20 2014-03-27 Aladar A. Szalay Compositions containing protein polymers and vaccinia virus, and methods of use thereof
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US20140271549A1 (en) 2013-03-15 2014-09-18 Aladar A. Szalay Use of Antibiotics to Enhance Treatment With Therapeutic Viruses
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
JP2018526428A (ja) 2015-09-09 2018-09-13 ティーブイエーエックス バイオメディカル アイ，リミティド ライアビリティ カンパニー 養子ｔ細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法

Also Published As

Publication number Publication date
US20230008052A1 (en) 2023-01-12
WO2012142529A3 (en) 2012-12-06
WO2012142529A2 (en) 2012-10-18
JP2014513938A (ja) 2014-06-19
JP6495513B2 (ja) 2019-04-03
EP2697368A2 (en) 2014-02-19
JP6415977B2 (ja) 2018-10-31
ES2733211T3 (es) 2019-11-28
US11149254B2 (en) 2021-10-19
CN104093830A (zh) 2014-10-08
CN114262690A (zh) 2022-04-01
EP2697368B1 (en) 2019-06-05
US20120308484A1 (en) 2012-12-06
JP2018171059A (ja) 2018-11-08
CA2836299A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
EA201301173A1 (ru) Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
PH12015501558A1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
EA201691487A1 (ru) Антитела человека к pd-l1
CY1121993T1 (el) Συνθεσεις που χαρακτηριζονται απο εναν εξασθενημενο ιο ψευδοπανωλης και μεθοδοι χρησης για την αντιμετωπιση της νέοπλασιας
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
NZ711946A (en) Newcastle disease viruses and uses thereof
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201401281A1 (ru) D-аминокислотные химические соединения для лечения заболеваний печени
BR112014029655A2 (pt) dispositivo para preparar tecido, e método para preparar tecido
EA201591501A1 (ru) Терапевтические средства на основе csf-1
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201591762A1 (ru) Человеческие антитела к grem1
EA201590332A1 (ru) Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA201400274A1 (ru) Связующая молекула, обладающая нейтрализующей активностью в отношении вируса гриппа а, полученная из в-клеток человека
EA201691314A1 (ru) Терапевтические способы и композиции
EA201790165A1 (ru) Происходящие от человека антитела к гентингтину (htt) и их применение
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201490201A1 (ru) Выявление экспрессии гена prame при раковом заболевании
EA201500232A1 (ru) Три(гетеро)арилпиразолы и их применение